Gender as an effect modifier in the relationship between hypertension and reticular pseudodrusen in patients with early or intermediate age-related macular degeneration.
gender
hypertension
intermediate age-related macular degeneration
reticular pseudodrusen
Journal
International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
07
2021
accepted:
03
12
2021
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
To determine whether the prevalence of treated hypertension is higher among males or females with early/intermediate (e/i) age-related macular degeneration (AMD) with and without bilateral reticular pseudodrusen (RPD). Retrospective review of the records of patients with e/iAMD who were recruited into the University of Colorado AMD registry between July 2014 and November 2019. Images were classified using the Beckman Initiative criteria and presence/absence of RPD. Patients were categorized into three groups: 1) e/iAMD with RPD; 2) e/iAMD without RPD; 3) control patients who did not have AMD. Multinomial logistic regression analysis was used for adjusted analysis with odds ratios (OR) and confidence intervals (CI). There were 260 patients with e/iAMD of which 101 had bilateral RPD and 159 had no RPD, and 221 controls. Overall, 62% of patients were female and the three groups did not differ by gender. When stratified by gender, the female e/iAMD/RPD group had a higher prevalence of hypertension, 64.1% Among females treated hypertension is significantly higher among e/iAMD/RPD patients, whereas for males there is no significant association.
Identifiants
pubmed: 35310058
doi: 10.18240/ijo.2022.03.14
pii: ijo-15-03-461
pmc: PMC8907055
doi:
Types de publication
Journal Article
Langues
eng
Pagination
461-465Subventions
Organisme : NEI NIH HHS
ID : R01 EY032456
Pays : United States
Informations de copyright
International Journal of Ophthalmology Press.
Références
Surv Ophthalmol. 2018 Nov - Dec;63(6):782-815
pubmed: 29859199
Circulation. 2012 Jan 3;125(1):e2-e220
pubmed: 22179539
PLoS One. 2014 Mar 28;9(3):e89600
pubmed: 24681973
Eur J Ophthalmol. 2021 Mar;31(2):505-513
pubmed: 32338527
BMJ Open Ophthalmol. 2020 Jan 14;5(1):e000361
pubmed: 32509962
Am J Ophthalmol. 2008 Feb;145(2):317-326
pubmed: 18045568
Invest Ophthalmol Vis Sci. 2014 Apr 25;55(4):2674-81
pubmed: 24651554
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Eur J Ophthalmol. 2020 Sep;30(5):1061-1068
pubmed: 31203676
Ophthalmology. 2019 Dec;126(12):1659-1666
pubmed: 31558345
Hypertension. 2017 Jul;70(1):19-26
pubmed: 28483918
Clin Ophthalmol. 2017 Sep 20;11:1707-1718
pubmed: 29033536
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
J Fr Ophtalmol. 1990;13(10):511-30
pubmed: 2081842
Eur Heart J. 2016 Jan 1;37(1):24-34
pubmed: 26530104
Br J Ophthalmol. 2018 Apr;102(4):483-489
pubmed: 28822985
Br J Ophthalmol. 1990 Nov;74(11):702-3
pubmed: 2223713
Am J Ophthalmol. 2014 May;157(5):985-993.e2
pubmed: 24491417